Welcome to our dedicated page for Imac Hldgs news (Ticker: BACK), a resource for investors and traders seeking the latest updates and insights on Imac Hldgs stock.
Overview of IMAC Holdings Inc
IMAC Holdings Inc (symbol: BACK) is a pioneer in the field of value-based, integrative medical care, combining advanced life science innovations with traditional medical practices. As an organization that emphasizes non-invasive treatments, IMAC Holdings focuses on providing innovative alternatives for the management of movement-restricting diseases and conditions. By blending cutting-edge regenerative therapies with a conservative care model, the company offers patients proven treatment protocols that mitigate the need for invasive surgeries such as knee or hip replacements, spinal fusion, and ligament transplants. Core industry keywords integrated in our approach include integrative medicine, regenerative therapy, and proteomics in order to deliver sustainable outcomes and reduced costs.
Business Model and Service Philosophy
IMAC Holdings Inc operates through its network of IMAC Regeneration Centers and BackSpace clinics, where the focus is on delivering conservative, value-based care that draws on both modern medical advancements and traditional healing techniques. The company emphasizes a patient-centric model by basing treatment protocols on the successful outcomes of previous patients. This track record is a testament to the effectiveness of their integrative procedures, which have been carefully refined over time to cater to a wide demographic—from elite athletes seeking peak recovery to seniors in need of non-invasive orthopedic treatments.
The business model is built around the following principles:
- Non-Invasive Treatment Protocols: By offering alternatives to invasive surgical procedures, IMAC Holdings reduces recovery times and associated healthcare costs.
- Integrative Medical Care: The convergence of traditional medical care with innovative regenerative procedures allows for personalized treatment strategies.
- Outcome-Based Approach: Patient outcomes and clinical results are the primary metrics driving the company’s care strategies.
- Advanced Diagnostic Techniques: Utilizing proteomic testing and biomarker analysis, the company enhances treatment specificity in various conditions, including those affecting joint and muscular integrity.
This model not only streamlines the treatment process but also positions IMAC Holdings as an essential player in the shift towards more sustainable and efficient healthcare solutions.
Clinical Services and Treatment Areas
At the heart of IMAC Holdings’ operations is the IMAC Regeneration Center, a specialized clinic designed to address a range of musculoskeletal ailments. The centers offer therapies aimed at alleviating knee pain, back pain, soft tissue and joint damage, muscular tears, arthritis, and other conditions that restrict patient movement. These non-surgical treatments emphasize enhancing patient quality of life, significantly reducing the pain and limitations associated with traditional operative interventions.
Key clinical service areas include:
- Musculoskeletal Rehabilitation: Focused on restoring mobility and function, these services provide a comprehensive alternative to invasive procedures.
- Integrative Physical and Medical Procedures: The combination of physical therapy techniques with targeted medical interventions offers a holistic treatment approach.
- Regenerative Medicine: Advanced procedures that harness the body’s natural healing capabilities, promoting recovery without the risks commonly associated with surgery.
- Proteomic Testing and Biomarker Analysis: Used to determine the most effective treatment modalities, these technologies ensure that therapy is tailored to individual patient needs.
The BackSpace clinics complement the Regeneration Centers by focusing on specialized patient care in unique settings, further extending the company’s reach in providing non-invasive, effective treatments.
Market Position and Industry Impact
IMAC Holdings Inc has established a niche within the integrative medicine and regenerative therapy sectors. Its approach is characterized by a strong emphasis on reducing overall healthcare costs while achieving superior patient outcomes. The company’s strategic use of advanced diagnostics and proteomic analysis sets it apart from traditional treatment providers, underlining its commitment to cutting-edge medical technologies. The integration of such methods with standard treatment practices has enabled IMAC Holdings to build considerable trust with both patients and healthcare professionals.
As alternative treatments gain traction, IMAC Holdings remains relevant in a competitive market where cost-effectiveness, patient safety, and quality care are at a premium. The company’s comprehensive, outcome-based approach ensures that it meets the evolving needs of its patient base while maintaining a rigorous standard of medical excellence.
Value Proposition and Patient Outcomes
The primary value offered by IMAC Holdings Inc is its commitment to quality care that is both innovative and grounded in proven medical practices. By focusing on non-invasive procedures that provide measurable clinical benefits, the company has consistently demonstrated that there is a viable alternative to traditional invasive surgeries. This approach not only improves the overall patient experience but also reduces the economic burden associated with long-term healthcare costs.
Patients benefit from:
- Customized Treatment Plans: Individual care protocols are developed based on detailed diagnostics and patient history, ensuring that therapies align with specific health needs.
- Reduced Recovery Times: Non-invasive procedures are associated with faster recoveries, allowing patients to return more rapidly to their daily activities.
- Lower Risk Profiles: By minimizing the need for surgery, the treatment plans inherently carry fewer risks and complications.
- Holistic Health Improvements: The combination of physical and medical care strategies promotes overall wellness beyond just symptom management.
Research and Development Integration
In addition to its clinical offerings, IMAC Holdings Inc invests in research and the development of new medical technologies. The company’s work in proteomics—measuring activated proteins—plays an increasingly important role in personalizing treatment protocols, especially in areas such as cancer therapy selection. Such integration of advanced diagnostics with patient care methodologies reflects the organization’s dedication to continuous improvement and scientific innovation.
Through strategic collaborations and a focus on evidence-based practice, IMAC Holdings not only refines its own treatment methodologies but also contributes valuable insights to the broader medical community. This dual commitment to clinical excellence and research underscores the company's role as an informed and authoritative voice in the healthcare field.
Operational Excellence and Patient Trust
Operational excellence is achieved through a rigorous focus on clinical outcomes and patient satisfaction. IMAC Holdings Inc has cultivated a reputation based on the reliable delivery of safe, effective, and innovative treatment alternatives. The patient-first approach, supported by ongoing evaluations and outcome assessments, ensures that every intervention is aligned with the highest standards of care and effectiveness.
Given its diverse patient base and broad range of services, the company has successfully positioned itself as a credible resource for individuals seeking advanced medical treatments without the inherent risks of invasive procedures.
Competitive Landscape and Differentiation
While the healthcare market is replete with providers offering both traditional and novel care treatments, IMAC Holdings Inc distinguishes itself through its clear focus on integrative, regenerative, and value-based care. Unlike practitioners who rely solely on conventional treatments or solely on advanced technological interventions, IMAC seamlessly integrates both strategies to deliver optimal patient outcomes. This multifaceted approach not only enhances treatment efficacy but also fosters long-term patient loyalty and satisfaction.
The differentiation is further emphasized by the company’s strict adherence to outcome-based care practices, ensuring that every clinical decision is informed by robust evidence and extensive experience. Such a methodical approach instills confidence among patients and healthcare professionals alike, affirming the company’s position within a competitive industry landscape.
Conclusion
In summary, IMAC Holdings Inc exemplifies a balanced integration of traditional medical expertise with modern regenerative and diagnostic technologies. The company has crafted a distinctive niche by focusing on non-invasive, value-based care that prioritizes patient outcomes and cost efficiency. Through its IMAC Regeneration Centers and BackSpace clinics, the organization delivers comprehensive treatments that not only alleviate pain and improve mobility but also provide an alternative to invasive surgical interventions. Its commitment to research, operational excellence, and patient trust continues to solidify its role as a reputable entity in the evolving fields of integrative and regenerative medicine.
The detailed structure of services, patient-focused treatment plans, and advanced diagnostic capabilities collectively underscore the company’s significance in modern healthcare. Investors and industry professionals alike can appreciate the depth of expertise and the authoritative approach that IMAC Holdings Inc employs in transforming patient care. This comprehensive overview serves as a reliable resource for understanding the operational and clinical dynamics of a company that is at the forefront of delivering innovative, conservative medical care.
Ignite Proteomics, a subsidiary of IMAC Holdings (Nasdaq: BACK), has announced groundbreaking data showing MHC-II protein expression as a superior predictor of pembrolizumab (Keytruda®) response compared to PD-L1. The findings will be presented at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference.
The study, conducted using I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies, including the commonly used companion diagnostic. Only MHC-II expression demonstrated statistically significant correlation with patient outcomes. Patients with higher MHC-II protein levels showed nearly double the response rate compared to unselected patients.
The I-SPY 2 trial, focusing on high-risk stage II and III breast cancer patients undergoing neoadjuvant treatment, is a multicenter, adaptive platform trial. The research suggests that MHC-II testing could significantly improve care by enabling more precise therapy decisions, particularly in cancer types where no biomarker testing is currently used.
Ignite Proteomics, a subsidiary of IMAC Holdings (Nasdaq: BACK), has completed the transfer of PLA code 0249U for its proteomic breast cancer assay, previously owned by Theralink Technologies. The code, listed on the Medicare Clinical Laboratory Fee Schedule with a reimbursement rate of $2,219.13, is covered under Palmetto GBA MolDx's 'Proteomics Testing' article (A59636).
The company's proteomic assay measures functional protein activity in breast tumors, offering oncologists data on potential patient responses to targeted therapies. The test is conducted in Ignite's CLIA-certified, CAP-accredited, and NY State-approved laboratory. This acquisition integrates both laboratory capabilities and intellectual property rights, positioning Ignite Proteomics to advance in precision oncology.
Ignite Proteomics, a subsidiary of IMAC Holdings (Nasdaq: BACK), has published a significant study in the British Journal of Cancer demonstrating the superiority of protein activation analysis in predicting breast cancer therapy response. The research reveals that direct assessment of protein activation provides better prediction of therapeutic outcomes compared to genomic profiling alone.
The study found that patients with functional activation of the AKT-mTOR signaling axis showed worse response to standard first-line treatment with CDK4/6 inhibitors. Importantly, genomic mutations in PIK3CA, PTEN, or AKT genes showed no correlation with protein activation status or patient outcomes.
The company's Reverse Phase Protein Array (RPPA)-based proteomic assay measures protein activation within the AKT-mTOR pathway, offering the only commercially available and clinically validated test that measures both expression and activation levels of drug targets in breast tumors. This approach enables more precise identification of patients likely to benefit from specific targeted therapies.
IMAC Holdings (NASDAQ: BACK) has launched Ignite Proteomics , a subsidiary focused on protein-based cancer treatment selection. The new venture aims to disrupt the multi-billion-dollar genomic testing market, with an immediate addressable market of $600M in its current clinically approved indication.
Unlike traditional genomic testing, Ignite's multi-protein test provides real-time insights into tumor behavior and drug response, particularly for antibody-drug conjugates (ADCs) and immunotherapies. The platform features novel biomarkers protected by licensed patents, offering physicians enhanced capabilities to select effective treatments and avoid trial-and-error approaches.
The company is actively collaborating with leading cancer centers to expand clinical evidence and integrate its test into routine care. The platform is particularly focused on breast cancer treatment guidelines and aims to provide more accurate insights than traditional gene-based testing methods.
IMAC Holdings (NASDAQ: BACK) has received a deficiency notification from Nasdaq due to its failure to timely file its Q3 2024 Form 10-Q. The company now has until January 21, 2024, to submit a compliance plan. If Nasdaq accepts the plan, IMAC may receive up to 180 calendar days (until May 19, 2025) to regain compliance. While the notice has no immediate effect on IMAC's stock listing, failure to regain compliance could result in delisting from Nasdaq Capital Market. The company intends to submit a compliance plan within the 60-day period but cannot guarantee success in maintaining its listing.
IMAC Holdings (NASDAQ: BACK) has received an extension from Nasdaq until February 17, 2025 to regain compliance with Listing Rule 5250(c)(1) by filing its Q2 2024 Form 10-Q. The delay in filing is attributed to three main factors: the acquisition of assets from Theralink Technologies, the exchange of Convertible Preferred Stocks and warrants, and staffing challenges including the temporary loss of a key financial staff member. The extension does not immediately affect the company's listing or trading status on the Nasdaq Capital Market.
IMAC Holdings Inc. (Nasdaq: BACK) has launched a new subsidiary, Ignite Proteomics , introducing a groundbreaking precision oncology assay for breast cancer treatment using Reverse Phase Protein Array (RPPA) technology. This follows IMAC's acquisition of key assets from Theralink Technologies, Inc. A landmark clinical case study published in npj Precision Oncology demonstrates the power of RPPA in precision oncology.
The case study highlights a 57-year-old woman with metastatic triple-negative breast cancer who achieved a complete response to therapy guided by Ignite's RPPA-based analysis. The assay identified HER2 expression and activation, missed by conventional methods, leading to successful treatment with trastuzumab deruxtecan (T-DXd).
Ignite Proteomics offers the only commercially available and clinically validated assay measuring both expression and activated protein drug target levels in breast tumors, potentially revolutionizing targeted cancer therapies.
IMAC Holdings (NASDAQ: BACK) has received a deficiency notification from Nasdaq due to the delayed filing of its Q2 2024 Form 10-Q. This non-compliance with Nasdaq Listing Rule 5250(c)(1) does not immediately affect the company's listing on the Nasdaq Capital Market. IMAC has until October 20, 2024, to submit a compliance plan and could potentially receive an extension until February 17, 2025, to regain compliance if Nasdaq accepts the plan. The company is working to file the Form 10-Q and take necessary steps to maintain its Nasdaq listing. However, there is no guarantee of success, and IMAC could face delisting if it fails to meet the requirements within the given timeframe.
IMAC Holdings has appointed Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move aims to advance IMAC’s position in proteomics and precision medicine. Dr. Schwartz, with over 18 years of experience in radiotherapy and precision oncology, and Dr. Beitsch, with a background in surgical oncology and genomics, will contribute their expertise to guide IMAC's strategic initiatives. Their appointments align with the company's mission to revolutionize cancer treatment through proteomic technologies.
IMAC Holdings announced a major leadership transition, appointing Faith Zaslavsky as CEO, succeeding Jeff Ervin. This move aims to drive forward its newly acquired assets in the proteomics and precision medicine industry.
Zaslavsky brings 23 years of experience in the genomic space, having previously served as COO and CEO of Theralink Technologies and President of Oncology at Myriad Genetics. Her leadership is expected to enhance IMAC's mission of providing personalized treatment plans for cancer patients.
IMAC's RPPA technology, proven through clinical trials as a superior indicator for drug selection in breast cancer, is set to become an essential test for various cancers. The board now consists of three independent members following the resignation of co-founders Dr. Matt Wallis and Jeff Ervin, with Ervin continuing as a transition consultant.
FAQ
What is the current stock price of Imac Hldgs (BACK)?
What is the market cap of Imac Hldgs (BACK)?
What services does IMAC Holdings Inc provide?
How does the company’s treatment approach differ from conventional methods?
What conditions are primarily addressed by IMAC Holdings Inc?
How does IMAC utilize proteomic testing in its services?
Who can benefit from the treatments offered by IMAC Holdings Inc?
What drives the value-based care model at IMAC Holdings Inc?
How does IMAC differentiate itself in the competitive healthcare market?
What should investors know about the company’s business model?
